Windlas Biotech Q3 FY26 results: revenue up 19.5% YoY, PAT dips sequentially
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 3.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Windlas Biotech reported Q3 FY26 consolidated revenue of Rs 2,331 million, up 19.5% YoY from Rs 1,950 million. Nine-month revenue rose 19.5% to Rs 6,656 million versus Rs 5,572 million. Q3 PAT was Rs 150 million against Rs 156 million YoY, while 9M PAT grew about 13% to Rs 505 million. EBITDA margins compressed as employee and other expenses rose faster than revenue. Board approved dissolution of non-operative US subsidiary Windlas Inc. Company paid Rs 5.80 per share dividend during the period.
Solid revenue growth but margin pressure and lower sequential PAT may temper sentiment. Subsidiary closure signals sharper portfolio focus.